Creo Medical Group PLC (LON:CREO - Get Free Report) was down 11.5% during mid-day trading on Thursday . The stock traded as low as GBX 14 ($0.19) and last traded at GBX 14.27 ($0.19). Approximately 3,943,218 shares traded hands during trading, an increase of 186% from the average daily volume of 1,380,099 shares. The stock had previously closed at GBX 16.13 ($0.22).
Creo Medical Group Trading Up 3.3%
The company has a debt-to-equity ratio of 29.96, a current ratio of 3.24 and a quick ratio of 2.19. The stock's 50 day moving average is GBX 11.09 and its 200-day moving average is GBX 14.83. The company has a market capitalization of £62.66 million, a P/E ratio of -2.45 and a beta of 0.86.
Creo Medical Group (LON:CREO - Get Free Report) last announced its earnings results on Monday, May 19th. The company reported GBX (8) (($0.11)) earnings per share (EPS) for the quarter. Creo Medical Group had a negative return on equity of 41.79% and a negative net margin of 73.93%. As a group, equities research analysts anticipate that Creo Medical Group PLC will post -10.0800005 earnings per share for the current year.
Insiders Place Their Bets
In other Creo Medical Group news, insider Kevin Crofton bought 701,750 shares of Creo Medical Group stock in a transaction dated Friday, May 30th. The shares were purchased at an average cost of GBX 16 ($0.22) per share, with a total value of £112,280 ($151,117.09). 22.43% of the stock is owned by corporate insiders.
About Creo Medical Group
(
Get Free Report)
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.
Featured Articles
Before you consider Creo Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Creo Medical Group wasn't on the list.
While Creo Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
